AbbVie: Communicable Diseases trials

The registry lists 40 Communicable Diseases studies with AbbVie as lead sponsor. 0 are open to participants now and 36 have results posted.

Phase 1 1Phase 2 12Phase 3 26Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)CompletedNCT03233438Phase 4Results posted
• Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)CompletedNCT02961764Phase 4Results posted
• Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSACompletedNCT02814916Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)CompletedNCT02738138Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 InfectionCompletedNCT02651194Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated CirrhosisCompletedNCT02642432Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 InfectionCompletedNCT02640482Phase 3Results posted
• A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric SubjectsCompletedNCT02486406Phase 2/3Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in BrazilCompletedNCT02442271Phase 3Results posted
• A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02356562Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02292719Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and CirrhosisCompletedNCT02219503Phase 3Results posted
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02219490Phase 3Results posted
• A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) InfectionCompletedNCT02216422Phase 3Results posted
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02167945Phase 3Results posted
• Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT02127970Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02023099Phase 3Results posted
• A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionCompletedNCT01939197Phase 2/3Results posted
• An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or BuprenorphineCompletedNCT01911845Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedNCT01854697Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced AdultsCompletedNCT01854528Phase 3Results posted
• A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a InfectionCompletedNCT01833533Phase 3Results posted
• A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant RecipientsCompletedNCT01782495Phase 2Results posted
• A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b InfectionCompletedNCT01767116Phase 3Results posted
• A Study to Evaluate Chronic Hepatitis C InfectionCompletedNCT01716585Phase 3Results posted
• A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced AdultsCompletedNCT01715415Phase 3Results posted
• A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus InfectionCompletedNCT01672983Phase 2Results posted
• Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01431339Phase 3Results posted
• Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01339091Phase 3Results posted
• Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infectionCompletedNCT01328158Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT01306617Phase 2Results posted
• A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin AmericaCompletedNCT01297504Results posted
• Treatment of Chlamydia Infection Comparing WC2031 Tablets With VibramycinCompletedNCT01113931Phase 3Results posted
• Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure InfectionsCompletedNCT00633152Phase 2Results posted
• Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin InfectionsCompletedNCT00424190Phase 3Results posted
• Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin InfectionsCompletedNCT00423657Phase 3Results posted
• Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial InfectionTerminatedNCT02688790Phase 1
• Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin InfectionsCompletedNCT01400867Phase 2/3
• Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract InfectionsCompletedNCT01281462Phase 2
• Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)CompletedNCT01128530Phase 2